|
1
|
McGuire A, Brown JA, Malone C, McLaughlin
R and Kerin MJ: Effects of age on the detection and management of
breast cancer. Cancers (Basel). 7:908–929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World Health Organization, International
agency for research on cancer, WHO press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Byler S, Goldgar S, Heerboth S, Leary M,
Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects
of breast cancer progression and therapy. Anticancer Res.
34:1071–1077. 2014.PubMed/NCBI
|
|
5
|
Scully OJ, Bay BH, Yip G and Yu Y: Breast
cancer metastasis. Cancer Genomics Proteomics. 9:311–320.
2012.PubMed/NCBI
|
|
6
|
Petit T, Dufour P and Tannock I: A
critical evaluation of the role of aromatase inhibitors as adjuvant
therapy for postmenopausal women with breast cancer. Endocr Relat
Cancer. 18:R79–R89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fu M, Maresh EL, Helguera GF, Kiyohara M,
Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, et
al: Rationale and preclinical efficacy of a novel anti-EMP2
antibody for the treatment of invasive breast cancer. Mol Cancer
Ther. 13:902–915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taherian-Fard A, Srihari S and Ragan MA:
Breast cancer classification: Linking molecular mechanisms to
disease prognosis. Brief Bioinform. 16:461–474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drabsch Y and ten Dijke P: TGF-β signaling
in breast cancer cell invasion and bone metastasis. J Mammary Gland
Biol Neoplasia. 16:97–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dimeo TA, Kristen A, Pushkar P, Fan C,
Perou CM, Naber S and Kuperwasser C: A novel lung metastasis
signature links Wnt signaling with cancer cell self-renewal and
epithelial-mesenchymal transition in basal-like breast cancer.
Cancer Res. 69:5364–5373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sethi N, Dai X, Winter CG and Kang Y:
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast
cancer by engaging notch signaling in bone cells. Cancer Cell.
19:192–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du WW, Fang L, Li M, Yang X, Liang Y, Peng
C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, et al: MicroRNA
miR-24 enhances tumor invasion and metastasis by targeting PTPN9
and PTPRF to promote EGF signaling. J Cell Sci. 126:1440–1453.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Washam CL, Byrum SD, Leitzel K, Ali SM,
Tackett AJ, Gaddy D, Sundermann SE, Lipton A and Suva LJ:
Identification of PTHrP(12–48) as a plasma biomarker associated
with breast cancer bone metastasis. Cancer Epidemiol Biomarkers
Prev. 22:972–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cabioglu N, Yazici MS, Arun B, Broglio KR,
Hortobagyi GN, Price JE and Sahin A: CCR7 and CXCR4 as novel
biomarkers predicting axillary lymph node metastasis in T1 breast
cancer. Clin Cancer Res. 11:5686–5693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Valastyan S, Reinhardt F, Benaich N,
Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and
Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits
breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hurst DR, Edmonds MD, Scott GK, Benz CC,
Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1
up-regulates miR-146, which suppresses breast cancer metastasis.
Cancer Res. 69:1279–1283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu Y, Qiu P and Ji Y: TCGA-assembler:
Open-source software for retrieving and processing TCGA data. Nat
Methods. 11:599–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rossini PM, Barker AT, Berardelli A,
Caramia MD, Caruso G, Cracco RQ, Dimitrijević MR, Hallett M,
Katayama Y, Lücking CH, et al: Non-invasive electrical and magnetic
stimulation of the brain, spinal cord and roots: Basic principles
and procedures for routine clinical application. Report of an IFCN
committee. Electroencephalogr Clin Neurophysiol. 91:79–92. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Farris JS: On the cophenetic correlation
coefficient. Syst Biol. 18:279–285. 1969.
|
|
20
|
Larsson O, Wahlestedt C and Timmons JA:
Considerations when using the significance analysis of microarrays
(SAM) algorithm. BMC Bioinformatics. 6:1292005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim KI and van de Wiel MA: Effects of
dependence in high-dimensional multiple testing problems. BMC
Bioinformatics. 9:1142008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haw R and Stein L: Using the reactome
database. Curr Protoc Bioinformatics. 8:Unit8.72012.PubMed/NCBI
|
|
24
|
Tu K, Yu H, Hua YJ, Li YY, Liu L, Xie L
and Li YX: Combinatorial network of primary and secondary
microRNA-driven regulatory mechanisms. Nucleic Acids Res.
37:5969–5980. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu H, Tu K, Wang YJ, Mao JZ, Xie L, Li YY
and Li YX: Combinatorial network of transcriptional regulation and
microRNA regulation in human cancer. BMC Syst Biol. 6:612012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liao YY, Lee TS and Lin YM: A Fisher exact
test will be more proper. Radiology. 239:300–301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Prasad TS Keshava, Goel R, Kandasamy K,
Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R,
Shafreen B, Venugopal A, et al: Human protein reference
database-2009 update. Nucleic Acids Res. 37(Database issue):
D767–D772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jang KW, Lee KH, Kim SH, Jin T, Choi EY,
Jeon HJ, Kim E, Han YS and Chung JH: Ubiquitin ligase CHIP induces
TRAF2 proteasomal degradation and NF-κB inactivation to regulate
breast cancer cell invasion. J Cell Biochem. 112:3612–3620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun LL, Wang J, Zhao ZJ, Liu N, Wang AL,
Ren HY, Yang F, Diao KX, Fu WN, Wan EH and Mi XY: Suppressive role
of miR-502-5p in breast cancer via downregulation of TRAF2. Oncol
Rep. 31:2085–2092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moroni M, Soldatenkov V, Zhang L, Zhang Y,
Stoica G, Gehan E, Rashidi B, Singh B, Ozdemirli M and Mueller SC:
Progressive loss of Syk and abnormal proliferation in breast cancer
cells. Cancer Res. 64:7346–7354. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Toyama T, Iwase H, Yamashita H, Hara Y,
Omoto Y, Sugiura H, Zhang Z and Fujii Y: Reduced expression of the
Syk gene is correlated with poor prognosis in human breast cancer.
Cancer Lett. 189:97–102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang X, Shrikhande U, Alicie BM, Zhou Q
and Geahlen RL: Role of the protein tyrosine kinase Syk in
regulating cell-cell adhesion and motility in breast cancer cells.
Mol Cancer Res. 7:634–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Malkas LH, Herbert BS, Abdel-Aziz W,
Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L,
Arnold RJ, et al: A cancer-associated PCNA expressed in breast
cancer has implications as a potential biomarker. Proc Natl Acad
Sci USA. 103:pp. 19472–19477. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He X, Arslan AD, Ho TT, Yuan C, Stampfer
MR and Beck WT: Involvement of polypyrimidine tract-binding protein
(PTBP1) in maintaining breast cancer cell growth and malignant
properties. Oncogenesis. 3:e842014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arslan AD, Asztalos S, Stampfer M, Tonetti
D, He X and Beck WT: PTBP1 stability is increased in ovarian and
breast cancer cell lines compared to matched controls. Cancer Res.
73:32012013. View Article : Google Scholar
|
|
36
|
Elias D, Vever H, Lænkholm AV, Gjerstorff
MF, Yde CW, Lykkesfeldt AE and Ditzel HJ: Gene expression profiling
identifies FYN as an important molecule in tamoxifen resistance and
a predictor of early recurrence in patients treated with endocrine
therapy. Oncogene. 34:1919–1927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yadav V and Denning MF: Fyn is induced by
Ras/PI3K/Akt signaling and is required for enhanced
invasion/migration. Mol Carcinog. 50:346–352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang Z, Jones R, Liu JC, Deng T, Robinson
T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM and
Zacksenhaus E: RB1 and p53 at the crossroad of EMT and
triple-negative breast cancer. Cell Cycle. 10:1563–1570. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robinson TJ, Liu JC, Vizeacoumar F, Sun T,
Maclean N, Egan SE, Schimmer AD, Datti A and Zacksenhaus E: RB1
status in triple negative breast cancer cells dictates response to
radiation treatment and selective therapeutic drugs. PLoS One.
8:e786412013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chano T, Ikebuchi K, Tomita Y, Jin Y,
Inaji H, Ishitobi M, Teramoto K, Ochi Y, Tameno H, Nishimura I, et
al: RB1CC1 together with RB1 and p53 predicts long-term survival in
Japanese breast cancer patients. PLoS One. 5:e157372010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lerebours F, Vacher S, Andrieu C, Espie M,
Marty M, Lidereau R and Bieche I: NF-kappa B genes have a major
role in inflammatory breast cancer. BMC Cancer. 8:412008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long
G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion
and migration in human breast cancer by targeting the RAB5A. Int J
Clin Exp Pathol. 8:384–393. 2015.PubMed/NCBI
|
|
43
|
Liu P, Tang H, Chen B, He Z, Deng M, Wu M,
Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour
proliferation and metastasis by targeting metadherin in triple
negative breast cancer. Cancer Lett. 357:384–392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J,
Cheng L, Fan Z, Yuan B, Tian P, et al: miR-30a suppresses breast
cancer cell proliferation and migration by targeting Eya2. Biochem
Biophys Res Commun. 445:314–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J,
Zhao JJ, Mao SS, Zhang GH, Xu XC and Zhang N: miR-340 inhibition of
breast cancer cell migration and invasion through targeting of
oncoprotein c-Met. Cancer. 117:2842–2852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ma F, Zhang J, Zhong L, Wang L, Liu Y,
Wang Y, Peng L and Guo B: Upregulated microRNA-301a in breast
cancer promotes tumor metastasis by targeting PTEN and activating
Wnt/β-catenin signaling. Gene. 535:191–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Arora H, Qureshi R and Park WY: miR-506
regulates epithelial mesenchymal transition in breast cancer cell
lines. PLoS One. 8:e642732013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang F, Lv P, Liu X, Zhu M and Qiu X:
MicroRNA-214 enhances the invasion ability of breast cancer cells
by targeting p53. Int J Mol Med. 35:1395–1402. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Inoue A, Omoto Y, Yamaguchi Y, Kiyama R
and Hayashi SI: Transcription factor EGR3 is involved in the
estrogen-signaling pathway in breast cancer cells. J Mol
Endocrinol. 32:649–661. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang SY, Liu SC, Al-Saleem LF, Holloran
D, Babb J, Guo X and Klein-Szanto AJ: E2F-1: A proliferative marker
of breast neoplasia. Cancer Epidemiol Biomarkers Prev. 9:395–401.
2000.PubMed/NCBI
|
|
51
|
Booy EP, Henson ES and Gibson SB:
Epidermal growth factor regulates Mcl-1 expression through the
MAPK-Elk-1 signalling pathway contributing to cell survival in
breast cancer. Oncogene. 30:2367–2378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Engel RH, Brown JA, Von Roenn JH, O'Regan
RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II
study of single agent bortezomib in patients with metastatic breast
cancer: A single institution experience. Cancer Invest. 25:733–737.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Schmid P, Kühnhardt D, Kiewe P,
Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J,
Niederle N, Brossart P, et al: A phase I/II study of bortezomib and
capecitabine in patients with metastatic breast cancer previously
treated with taxanes and/or anthracyclines. Ann Oncol. 19:871–876.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Burstein HJ, Elias AD, Rugo HS, Cobleigh
MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo
SE, et al: Phase II study of sunitinib malate, an oral
multitargeted tyrosine kinase inhibitor, in patients with
metastatic breast cancer previously treated with an anthracycline
and a taxane. J Clin Oncol. 26:1810–1816. 2008. View Article : Google Scholar : PubMed/NCBI
|
